Company intelligence / Profile preview

Sapphire Biotech

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Sapphire Biotech was a California-based oncology biotech that developed preclinical small molecule inhibitors of QSOX1 for cancer therapy and rapid QSOX1-L biomarker diagnostic tests. Their anti-metastatic compounds included SPX-1009, which demonstrated higher potency than SBI-183. The company was acquired by AXIM Biotechnologies in January 2020.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

SBI-183

Preclinical

Partnerships

Mayo ClinicArizona State UniversitySkysong Innovations (licensing partner)

Beyond the preview

Go deeper on Sapphire Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sapphire Biotech.

Explore the full profile